Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

One of the research challenges in oncology is to develop new biochemical methods for noninvasive tumor therapy evaluation to determine whether the chemotherapeutics is effective. Vascular endothelial growth factor (VEGF) was labeled with radioiodine and evaluated in vitro as well as in vivo, using A2058, a melanoma cell line overexpressing VEGFR-1 and -2. Saturation binding analysis with [(125)I]-VEGF resulted in a K(d) of 0.1 nM. Internalization assays indicate the preserved ligand induced internalization and metabolization of the tracer. Biodistribution studies with [(123)I]-VEGF in wild type and A2058 tumor-bearing athymic mice showed low background activity and a tumor to reference tissue ratio of maximum 6.12. These results suggest that [(123)I]-VEGF is a potentially suitable tracer for tumor therapy evaluation.

Original publication

DOI

10.1016/j.nucmedbio.2005.03.005

Type

Journal article

Journal

Nucl Med Biol

Publication Date

07/2005

Volume

32

Pages

431 - 436

Keywords

Animals, Cell Line, Tumor, Humans, Iodine Radioisotopes, Male, Melanoma, Mice, Receptors, Vascular Endothelial Growth Factor, Tissue Distribution, Vascular Endothelial Growth Factor A